http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-089701-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f957d1845704efe460ce093473dae25a |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C255-60 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D213-60 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C317-44 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C323-60 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D213-61 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C317-44 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-44 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D213-72 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D213-60 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-167 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C255-60 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4427 |
| filingDate | 2013-01-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2014-09-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-089701-A1 |
| titleOfInvention | ARILAMIDE DERIVATIVES THAT HAVE ANTIANDROGENIC PROPERTIES |
| abstract | Compounds with anticancer effects. Claim 1: An arylamide derivative having the formula (1) or a stereoisomer or pharmaceutically acceptable salt thereof; wherein A is selected from the group consisting of H, halogen, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₂ perhaloalkyl, C₁₋₆ hydroxyhaloalkyl, C₁₋₆ aminoalkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkoxy, perhaloalkoxy C₁₋₂, C₁₋₂-Cque-alkenyl alkoxy, C₁₋₆ alkylsulfonyl, arylsulfonyl, and NHR, wherein R is H or C₁₋₆ alkyl; arylamide, C₁₋₆ alkylamide, arylsulfonamide, C₁₋₆ alkylsulfonamide, and aryl; R and R each independently is selected from the group consisting of H and C₁₋₆ alkyl; z is an integer from 0 to 3; RA is a mono or bicyclic, aromatic or heteroaromatic ring system having 6 to 10 ring atoms, whereby said mono or bicyclic ring system comprises 0 to 2 or 0 to 4 nitrogen atoms in the ring, respectively, and the other atoms in the ring are carbon atoms, said ring system is not substituted or substituted one or more times, and where said substituents can be located at any appropriate location and are represented by RA; each RA is independently selected from the group consisting of halogen, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₂ perhaloalkyl, hydroxy, C₁₋₆ alkoxy, NO₂, CN, C (O) R, COOR, CONHR, NR₂, NHCOR, NHCOCF₃, NHCONHR, NHCOOR, OCONHR, where each R is independently hydrogen or C₁₋₆ alkyl, and (CH₂) ₙCHO, where n is an integer from 0-6; or when RA is a monocyclic ring, two adjacent RAs can be joined together to form a substituted or unsubstituted bridge; RB is an aromatic or heteroaromatic ring system having 6 atoms in the ring comprising 0 to 2 nitrogen atoms in the ring, while the other atoms in the ring are carbon atoms, said ring system is substituted one or more times, and where said substituents may be located at any appropriate location and are represented by RB; each RB is independently selected from the group consisting of halogen, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₂ perhaloalkyl, hydroxy, C₁₋₆ alkoxy, NO₂, CN, C (O) R, COOR, CONHR, NR₂, NHCOR, NHCOCF₃, NHCONHR, NHCOOR, OCONHR, SR, S (O) R, SO₂R, and NHCSCH₃, where R is as defined above; or two adjacent RBs can form with the carbon atoms, to which they are attached, an aliphatic or heteroaliphatic, aromatic or heteroaromatic substituted or unsubstituted ring; X is selected from the group consisting of O, S, S (O), SO₂, and NR, where R is selected from the group consisting of H, C₁₋₆ alkyl, and COR, where R is as defined above; or when z is 0, then X can be N and together with RC form a heterocyclic ring selected from the group consisting of morpholine, 1,2,4-triazole, imidazole and N-substituted imidazole; and RC, when it does not form a ring with X as defined above, is selected from the group consisting of H, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₃₋₄ cycloalkyl, C₁₋₆ haloalkyl, C₁₋₂ perhaloalkyl, C₂₋₆ haloalkenyl, CN-C₁₋₆ alkyl, C₁₋₆ alkoxy, and a 5-7 membered aliphatic or heteroaliphatic ring, ring systems that are optionally substituted with one or more substituents, and wherein said Substituents may be located at any suitable location and represented by RC, each RC is independently selected from the group consisting of halogen, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₂ perhaloalkyl, hydroxy, C₁₋₆ alkoxy, NO₂ , CN, C (O) R, COOR, CONHR, NR₂, NHCOR, NHCOCF₃, NHCONHR, NHCOOR, OCONHR, NHSO₂R, SR, S (O) R, SO₂R, and NHCSCH₃, where R is as defined above. |
| priorityDate | 2012-01-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 34.